Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Manali says Epco-R2 caused grade 3 or higher neutropenia in 69% of patients, so co-management with community partners often means dose-reducing or holding lenalidomide to keep epcoritamab going. This practical lever matters as the triplet enters second-line follicular lymphoma practice. It may prevent unnecessary epcoritamab discontinuation.

Related Insights

While CELMoDs frequently cause neutropenia, this effect is most pronounced in early cycles and manageable with growth factors. This contrasts sharply with the persistent, quality-of-life-impairing non-hematologic side effects of lenalidomide, such as rash and severe fatigue. This trade-off results in a significantly better long-term tolerability profile for patients.

The phase 3 EPCOR FL-1 trial showed that adding epcoritamab to the lenalidomide/rituximab (R-squared) backbone profoundly improved progression-free survival in relapsed follicular lymphoma. Presented as the most important FL abstract at ASH, this result is expected to establish a new standard of care in this setting.

A novel trial design used mosinutuzumab monotherapy first in frontline follicular lymphoma, adding lenalidomide only for patients without a complete response. This adaptive approach successfully spared about two-thirds of patients from the added toxicities of lenalidomide while still achieving very high overall efficacy.

Contrary to expectations, adding Tafasitamab and Lenalidomide to the R-CHOP regimen for diffuse large B-cell lymphoma resulted in only a marginal increase in toxicity. The rate of high-grade febrile neutropenia was only 3-4% higher, a pleasant surprise compared to previous combination trials.

A modified three-step-up dosing schedule for epcoritamab drastically reduced cytokine release syndrome (CRS) rates to 26%, with no severe events. This safety profile supports fully outpatient administration, making this highly effective regimen accessible to community practices without immediate hospital access.

Manali reports Epco-R2's phase 3 follicular lymphoma trial showed a hazard ratio of 0.2 for PFS, but grade 3 or higher infections hit 33% and neutropenia 69%. MosinLen had less infection and is a time-limited doublet. If approved, the choice may trade triplet efficacy for better tolerability.

A patient in the BELLA trial with recurrent grade 3 neutropenia avoided treatment discontinuation through dose modification. By skipping the day 8 dose and switching to a day 1 and 15 every 28-day schedule, the patient could tolerate and continue the beneficial therapy, showcasing a practical clinical strategy for managing severe toxicity.

Epcoritamab combined with lenalidomide and rituximab (EPCO R-squared) is now considered the preferred second-line regimen for most follicular lymphoma patients. It has demonstrated superior efficacy compared to the tafasitamab plus R-squared regimen, effectively 'knocking it off its perch' as the standard in this setting.

For older, transplant-ineligible myeloma patients, quadruplet regimens are not administered at full strength. Clinicians proactively reduce doses of bortezomib, lenalidomide, and dexamethasone based on patient fitness and renal function to manage toxicity while maintaining efficacy.

An MD Anderson study showed that delaying the addition of obinutuzumab to an acalabrutinib-venetoclax regimen achieved similar deep remission rates (uMRD) as upfront administration. This sequencing strategy significantly reduced severe neutropenia (52% vs 12%) and infections, making the potent combination safer.

Triplet neutropenia can be managed by holding lenalidomide | RiffOn